• Loss down 54.3% to $2.716 million
• Progressed phase 2 trials of lead candidate SNT-5505 in myelofibrosis
• Commenced new phase 2 trials of SNT-5505 in myelodysplastic syndrome

Syntara Limited, a clinical-stage drug development company, has reported its half-year results for the period ended 31 December 2024. The company's loss for the half-year amounted to $2,716,000, a decrease of 54.3% compared to the previous corresponding period. Syntara's primary focus is the development of its pan-Lysyl Oxidase (pan-LOX) inhibitor program, with lead candidate SNT-5505 being evaluated for the treatment of myelofibrosis (MF) and myelodysplastic syndrome (MDS). In MF, the company completed the phase 1c stage of the MF-101 clinical trial and commenced a new combination arm with a JAK inhibitor. Interim data from this trial showed significant improvements in symptom relief and spleen volume reduction, with the combination therapy being well-tolerated. Syntara also announced new phase 2 trials of SNT-5505 in MDS, including a study in collaboration with the University of Newcastle and Australasian Leukaemia and Lymphoma Group, as well as a study in Germany funded by Deutsche Krebshilfe. Additionally, the company has explored the potential of SNT-5505 in other cancers, such as hepatocellular carcinoma and pancreatic cancer, through various scientific collaborations. Syntara also has a topical pan-LOX inhibitor program, SNT-6302, for scar revision and prevention, as well as an SSAO inhibitor program, SNT-4728, for the treatment of sleep disorders and neurodegenerative diseases.